Arecor Therapeutics plc




Biotechnology & Medical Research

Market Closed - London S.E. 11:35:24 2024-04-24 am EDT 5-day change 1st Jan Change
136.5 GBX +3.02% Intraday chart for Arecor Therapeutics plc +5.00% -25.21%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Arecor chief financial officer to leave in July after five years AN
Arecor Therapeutics CFO to Leave in July MT
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Chief Financial Officer, Effective from July 22, 2024 CI
Arecor Therapeutics plc Announces Stepping Down of Susan Lowther as Company Secretary and as A Board Director, Effective from July 22,2024 CI
Arecor to develop "holy grail" diabetes treatment with partner TRx AN
Arecor Therapeutics plc and Trx Biosciences Limited Announces Research Collaboration for the Formulation Development of an Oral GLP-1 Receptor Agonist Product CI
EARNINGS AND TRADING: East Star, Getech strike Kazakhstan JV AN
Arecor Therapeutics hails Arestat as 2023 performance "strong" AN
Arecor pleased as investee Inhibrx sells therapy to Sanofi AN
Patent boosts for DG Innovate and Arecor Therapeutics AN
Arecor Therapeutics Gains European Patent for Insulin Product Formulations MT
Arecor expands speciality hospital collaboration with partner AN
Arecor Therapeutics Expands Formulation Study Collaboration with Pharmaceutical Partner MT
Arecor Therapeutics plc Expands Ongoing, Exclusive Formulation Study Collaboration with the Pharmaceutical Division of One of the World's Largest Chemicals Marketing and Pharmaceuticals Companies CI
Arecor inks co-development deal with global medical company AN
Arecor Therapeutics Signs Exclusive License Option Agreement for Oncology Product MT
Arecor Therapeutics plc Announces Co-Development and Exclusive Licence Option Agreement CI
Arecor inks Eli Lilly deal; RBG appoints McNair CFO AN
Arecor Therapeutics Signs Further Collaboration With Eli Lilly MT
Arecor Therapeutics plc Signs Further Collaboration Agreement with Lilly and Company CI
Arecor Therapeutics gets "milestone payment" from AT220 sale AN
Arecor Therapeutics to Receive Milestone Payment from Maiden Commercial Sale of Arestat Technology Product MT
Troy Income suspends buyback of shares AN
Arecor Therapeutics to Receive Milestone Payment from Inhibrx MT
Arecor Therapeutics ups subject numbers for insulin-focused trial AN
Chart Arecor Therapeutics plc
More charts
Arecor Therapeutics plc is a United Kingdom-based globally focused biopharmaceutical company. The Company, by applying its technology platform, Arestat, is developing an internal portfolio of products in diabetes and other indications, as well as working with pharmaceutical and biotechnology companies to deliver therapeutic products. Its portfolio includes AT247 - Ultra-Rapid Acting Insulin and AT278 - Ultra-Concentrated Ultra-Rapid Acting Insulin. Its lead product, AT247, is an Arestat enabled formulation of insulin designed to accelerate insulin absorption post injection, to enable effective management of blood glucose levels for people living with diabetes, particularly around difficult to manage mealtimes. The Company's AT278 is an ultra-concentrated novel formulation of ultra-rapid acting insulin. Its subsidiary, Tetris Pharma Ltd, has a portfolio of injectable products including Ogluo, which is a ready-to-use glucagon for emergency use to treat hypoglycemia.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
More Ratings
Mean consensus
Number of Analysts
Last Close Price
1.325 GBP
Average target price
4.71 GBP
Spread / Average Target

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. AREC Stock
  4. News Arecor Therapeutics plc
  5. Arecor Therapeutics Gains European Patent for Insulin Product Formulations